Skip to main content
. Author manuscript; available in PMC: 2008 Oct 1.
Published in final edited form as: J Neuroimmunol. 2007 Sep 4;190(1-2):139–145. doi: 10.1016/j.jneuroim.2007.07.016

Figure 4.

Figure 4

Measurement of IFN-γ in activated remitting patient samples in the presence or absence of calpain inhibitor, calpeptin. PBMCs, isolated from MS patients (n=3) were activated with anti-CD3/CD28 plus or minus calpeptin (100μM). PBMCs treated with media alone were used as control (vehicle). Supernatants were collected after 24 hours for analysis of IFN-γ using IFN-γ-specific ELISA kit. It is important to note that the patient samples without activation produced significant amount of IFN-γ (vehicle).